SAT-LB16 Maintenance of Favorable Treatment Effect of Once-Weekly TransCon hGH for Children With Growth Hormone Deficiency: Interim Analysis From the Enlighten Long-Term Extension Trial

Background Once-weekly TransCon hGH is an investigational long-acting prodrug for growth hormone deficiency (GHD) that consists of 3 components: unmodified growth hormone (hGH; somatropin), an inert carrier that protects it, and a linker that temporarily binds the two. In the randomized phase 3 heiG...

Descripción completa

Detalles Bibliográficos
Autores principales: Maniatis, Aristides K, Casella, Samuel J, Nadgir, Ulhas M, Mick, Gail J, Hofman, Paul, Saenger, Paul, Chertok, Elena D, Warshauer, Jeremy, Song, Wenjie, Peng, Jessica M, Komirenko, Allison S, Shu, Aimee D, Beckert, Michael, Aghajanova, Elena M, Thornton, Paul S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Pediatric Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209480/
http://dx.doi.org/10.1210/jendso/bvaa046.2102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209480/
http://dx.doi.org/10.1210/jendso/bvaa046.2102

Ejemplares similares